Champions Oncology (CSBR) AI Stock Analysis

• Market Cap: $95.00M
• Dividend Yield: N/A
• Average Volume (3M): 28.68K
• Price to Earnings (P/E): 34.1
• Beta (1Y): 0.38
• Revenue Growth: 10.11%
• EPS Growth: N/A
• Country: US
• Employees: 210
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 13,788,421
• 10 Day Avg. Volume: 11,385
• 30 Day Avg. Volume: 28,685
• PEG Ratio: -0.13
• Price to Book (P/B): 25.89
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 13.96
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 5.94
• Enterprise Value/Ebitda: 23.56
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: $6.50 ▼(-2.11% Downside)

Champions Oncology's stock score is primarily influenced by financial performance and technical analysis. While profitability has improved, high leverage and declining cash flow growth pose significant risks. The technical indicators suggest no strong trend, and the valuation appears stretched. The earnings call provides some positive developments, but challenges remain.

Champions Oncology Business Overview & Revenue Model

Company Description

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

How the Company Makes Money

Champions Oncology generates revenue through multiple streams, primarily from its services related to TumorGraft technology. The company earns money by providing tumor model services to pharmaceutical and biotechnology companies for their drug development processes, including preclinical testing and personalized medicine applications. Additionally, CSBR may receive revenue from collaborations and partnerships with larger pharmaceutical firms that seek to utilize its TumorGraft technology in clinical trials. The company may also generate income from licensing agreements and research collaborations that leverage its expertise in cancer modeling and treatment personalization. Overall, the combination of service fees, collaborative agreements, and licensing contributes significantly to the company's earnings.

Champions Oncology Financial Statement Overview

Summary

Champions Oncology's financial statements depict a company facing significant challenges in revenue stability and cash management, despite some improvements in equity and net income. The high leverage and inconsistent profit margins reflect potential risks, while cash flow issues underscore liquidity concerns. Overall, the company is in a transitional phase, showing both vulnerabilities and some recovery indicators.

Income Statement

The company exhibits a volatile income statement with a negative gross profit margin in TTM, indicating more costs than revenue. Despite a positive net income in TTM, the revenue growth rate is negative, showing declining sales over time. Margins are inconsistent, with significant fluctuations in EBIT and EBITDA margins. The overall income statement suggests instability in revenue generation and cost management.

Balance Sheet

The balance sheet reveals a concerning debt-to-equity ratio, indicating high leverage. However, the TTM data shows improved stockholders' equity, suggesting a recovery trend. ROE is positive in TTM, reflecting recent profitability. The equity ratio remains low, indicating potential financial risk due to dependence on liabilities. The balance sheet points to a moderate risk profile with some signs of recovery.

Cash Flow

Cash flow analysis shows negative free cash flow growth in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash outflows even with positive net income. This trend suggests problems in converting earnings into cash. The cash flow statement highlights liquidity challenges and inefficiencies in cash operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	42.88M	56.94M	50.16M	53.87M	49.11M	41.04M
Gross Profit	13.93M	28.55M	20.75M	24.34M	25.48M	19.57M
EBITDA	3.51M	6.49M	-5.05M	-2.07M	2.23M	366.00K
Net Income	2.92M	4.70M	-7.28M	-5.33M	548.00K	362.00K
Balance Sheet
Total Assets	30.55M	32.34M	26.13M	34.31M	35.38M	27.59M
Cash, Cash Equivalents and Short-Term Investments	10.32M	9.79M	2.62M	10.12M	9.01M	4.69M
Total Debt	5.75M	6.11M	7.43M	8.60M	9.47M	9.60M
Total Liabilities	27.01M	28.57M	28.04M	29.68M	26.28M	20.16M
Stockholders Equity	3.51M	3.77M	-1.90M	4.64M	9.10M	7.43M
Cash Flow
Free Cash Flow	7.24M	7.00M	-6.97M	1.08M	4.11M	-4.96M
Operating Cash Flow	7.67M	7.39M	-6.14M	3.96M	6.50M	-1.68M
Investing Cash Flow	-435.00K	-389.00K	-836.00K	-2.87M	-2.38M	-3.17M
Financing Cash Flow	193.00K	170.00K	-527.00K	11.00K	207.00K	1.20M

Champions Oncology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.64
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Positive. The current price of 6.64 is above the 20-day moving average (MA) of 6.54, below the 50-day MA of 6.73, and below the 200-day MA of 7.88, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.51 is Neutral, neither overbought nor oversold. The STOCH value of 84.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSBR.

Champions Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	―	$188.17M	32.16	15.99%	―	62.79%	―
CSBR	―	$95.00M	34.13	185.89%	―	10.11%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIX	―	$136.28M	-12.57	-57.94%	―	―	11.78%
SAVA	―	$182.60M	―	-88.95%	―	―	-553.86%
ATOS	―	$120.41M	-4.19	-41.66%	―	―	-8.91%

Champions Oncology Corporate Events

Champions Oncology Holds Annual Stockholders Meeting

On October 16, 2025, Champions Oncology, Inc. held its Annual Meeting of Stockholders, where key decisions were made. The company’s seven director nominees were elected for a one-year term, and the appointment of EisnerAmper LLP as the independent registered public accounting firm was ratified. Additionally, a non-binding advisory resolution on executive compensation was approved, indicating shareholder support for the company’s leadership and strategic direction.

The most recent analyst rating on (CSBR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Champions Oncology stock, see the CSBR Stock Forecast page.

Champions Oncology Earnings Call: Cautious Optimism Amid Challenges

The recent earnings call for Champions Oncology reflects a company in transition, with signs of recovery and growth tempered by ongoing challenges. The sentiment expressed during the call was one of cautious optimism, as the company reported a rebound in revenue and strong momentum in its data platform and radiopharmaceutical services. However, flat year-over-year revenue, an operating loss, and decreased gross margins highlight the hurdles that remain. Despite these challenges, the company maintains a stable financial position with a strong cash reserve and no debt.

Champions Oncology Reports Steady Revenue and New Leadership

Champions Oncology, Inc. is a global preclinical and clinical research services provider specializing in oncology R&D solutions for biopharma organizations, known for its extensive bank of patient-derived xenograft models and innovative bioanalytical platforms. In its latest earnings report for the first quarter of fiscal 2026, Champions Oncology reported a total revenue of $14 million, with an adjusted EBITDA of $60,000, marking a positive start to the fiscal year despite a slight decline in revenue compared to the previous year. Key highlights include the appointment of Rob Brainin as the new CEO, who aims to drive the company’s growth through its core services and emerging data platform, as well as a focus on scientific excellence and collaboration. Financially, the company experienced a loss from operations amounting to $527,000, primarily due to increased costs and operating expenses, including higher outsourced lab services and investments in its data licensing platform. Looking ahead, Champions Oncology’s management remains optimistic about continued revenue growth and margin improvement, supported by a strong services pipeline and increasing demand for its data offerings, positioning the company for long-term success.

Champions Oncology Reports Record Revenue and Profitability

The latest earnings call for Champions Oncology paints a picture of a company on the upswing, with notable achievements such as record revenue and a return to profitability. The sentiment was largely positive, buoyed by successful data licensing deals. However, the call also acknowledged ongoing challenges, including a decline in Q4 revenue and gross margin, as well as market constraints affecting the biotech and pharma sectors.